English
Back
Download
Log in to access Online Inquiry
Back to the Top

T 1 news halt!

$Relmada Therapeutics (RLMD.US)$ Press Release: Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
Dow Jones· 5 mins ago
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize Shareholder Value
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
110K Views
Comment
Sign in to post a comment
    4489
    Followers
    25
    Following
    64K
    Visitors
    Follow
    Discussing
    Trump 2.0 countdown: What's the next big opportunity in the markets?
    🎙️️ Discussion: 1. Could Trump's cryptocurrency policies potentially benefit the crypto market? 2. Might his tariff policies have a positiv Show More